Aclaris Therapeutics (ACRS) Cash & Equivalents (2014 - 2026)

Aclaris Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $28.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 5.59% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $28.7 million (down 5.59% YoY), while the FY2025 annual figure was $20.0 million, down 18.76% from the prior year.
• Cash & Equivalents was $28.7 million for Q1 2026 at Aclaris Therapeutics, up from $20.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $68.3 million in Q2 2022 to a low of $20.0 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $36.9 million across 5 years, with a median of $35.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 65.55% in 2022, then plunged 54.37% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $45.3 million in 2022, then slipped by 11.92% to $39.9 million in 2023, then plunged by 38.39% to $24.6 million in 2024, then declined by 18.76% to $20.0 million in 2025, then jumped by 43.59% to $28.7 million in 2026.
• The last three Cash & Equivalents figures came in at $28.7 million (Q1 2026), $20.0 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.